In this retrospective study, we examine the therapeutic efficacy of ICIs alone or in combination in patients with EGFR mutated NSCLC, founding that a combination of ICIs and anti-angiogenic agents plus chemotherapy would lead to longer PFS and OS, while safety profile is tolerable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.